Company Encyclopedia
View More
name
Nanoviricides
NNVC.US
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses.
1.946 T
NNVC.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NanoViricides Signs Master Services Agreement with Only Orphans Cote for Orphan Drug Strategy

    NanoViricides Inc. has signed a Master Services Agreement with Only Orphans Cote, LLC to develop an orphan drug strategy for its antiviral candidate NV-387. The agreement involves preparing and prosecuting orphan drug designation applications with the US FDA. This collaboration aims to advance NV-387's regulatory pathway as an orphan drug.

    Reuters·
    US
    NNVC
    +9.91%
    Reuters·
    US
    NNVC
    +9.91%

    NanoViricides Inc. Held Annual Shareholder Meeting

    NanoViricides Inc. held its annual shareholder meeting on November 22, 2025. Shareholders re-elected Anil Diwan as director, approved executive compensation, and ratified EisnerAmper, LLP as the accounting firm for fiscal year ending June 30, 2026.

    Reuters·
    US
    NNVC
    +9.91%
    Reuters·
    US
    NNVC
    +9.91%

    NanoViricides Secures $6 Million Through Securities Offering

    NanoViricides, Inc. raised $6 million through a securities purchase agreement with an institutional investor, involving a registered direct offering and private placement. The funds will be used for working capital and corporate purposes, enhancing its drug development efforts. Despite weak financial performance and negative earnings, the company shows short-term positive momentum. NanoViricides specializes in antiviral therapy, with lead drug candidates targeting viral infections like RSV, COVID-19, and Shingles.

    Tip Ranks·
    US
    NNVC
    +9.91%
    Tip Ranks·
    US
    NNVC
    +9.91%

    Nanoviricides | 10-Q: FY2026 Q1 Revenue: USD 0

    LB filings·
    US
    NNVC
    +9.91%
    LB filings·
    US
    NNVC
    +9.91%

    NanoViricides Launches Private Placement of Warrants in $6 Million Funding Deal

    NanoViricides Inc. announced a private placement of Series A and B warrants in a $6 million funding deal. The Series A warrants have a $1.75 exercise price, expiring in 2 years, while Series B warrants have a $2.00 exercise price, expiring in 5.5 years. These are offered under SEC registration exemption.

    Reuters·
    US
    NNVC
    +9.91%
    Reuters·
    US
    NNVC
    +9.91%
    © 2025 Longbridge｜Disclaimer